Metabolic Profiling of Brain Metastases Using MR Spectroscopy
Author Information
Author(s): Torill E Sjøbakk, Roar Johansen, Tone F Bathen, Ursula Sonnewald, Kjell A Kvistad, Steinar Lundgren, Ingrid S Gribbestad
Primary Institution: Norwegian University of Science and Technology (NTNU)
Hypothesis
In vivo MRS from different brain metastases analysed by multivariate analyses distinguish metastases originating from different primary tumors, and also that MR spectra can indicate clinical outcome for these patients.
Conclusion
MR spectroscopy can provide valuable clinical information for planning and evaluating the treatment of brain metastases.
Supporting Evidence
- The PCA results indicated that brain metastases from primary lung and breast cancer were separated into two clusters.
- The PLS analysis showed a significant correlation between MR spectral data and survival five months after MRS before start of treatment.
- The study found that lipid signals are important in brain metastases characterization.
Takeaway
Doctors can use special scans to see how brain tumors from different cancers behave, which helps them decide the best treatment.
Methodology
Patients with brain metastases underwent single voxel MRS at a 3T MR system, and multivariate analyses were used to assess the data.
Potential Biases
The distribution of primary cancer types among patients was skewed, with more patients having breast and lung cancer.
Limitations
The study had a small and heterogeneous group of patients, which may affect the generalizability of the results.
Participant Demographics
The study included 26 patients (18 women and 8 men) with brain metastases from various primary cancers.
Statistical Information
P-Value
0.01
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website